Use of proton pump inhibitors increased the risk of hip fracture: A population-based case-control study

Pharmacoepidemiology and Drug Safety

Volumn 19, Issue 11, 2010, Pages 1131-1136

  Chiu, Hui Fen ^a   Huang, Ya Wen ^b   Chang, Chih Ching ^c   Yang, Chun Yuh ^b  

^a KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^c NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

Author keywords

Hip fractures; Pharmacoepidemiology; PPI; Proton pump inhibitors

Indexed keywords

PROTON PUMP INHIBITOR;

ADVERSE OUTCOME; AGED; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG SAFETY; DRUG USE; FEMALE; HIP FRACTURE; HUMAN; MAJOR CLINICAL STUDY; MALE; POPULATION BASED CASE CONTROL STUDY; PRESCRIPTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; TAIWAN;

AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; DATABASES, FACTUAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HIP FRACTURES; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROTON PUMP INHIBITORS; RETROSPECTIVE STUDIES; TAIWAN;

EID: 78049300965     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.2026     Document Type: Article

References (18)

1. 2 receptor antagonists, and other antacid medications and the risk of fracture. Calcif Tissue Int 2006; 79: 76-83.
2. ase, on bone resorption in humans. Calcif Tissue Int 1993; 53: 21-25.
3. O'Connell MB, Madden DM, Murray AM, Heaney RP, Kerzner LJ. Effects of ptoton pump inhibitors on calcium carbonate absorption in women: a randomized crossover trial. Am J Med 2005; 118: 778-781.
4. Yang YX, Lewis JD, Epstein S, Metz DC. Long-term proton pump inhibitor therapy and risk of hip fracture. J Am Med Assoc 2006; 296: 2947-2953.
5. Kaye JA, Jick H. Proton pump inhibitor therapy use and risk of hip fractures in patients without major risk factors. Pharmacotherapy 2008; 28: 951-959.
6. Targownik LE, Lix LM, Metge CJ, Prior HJ, Leung S, Leslie WD. Use of proton pump inhibitors and risk of osteoporosis- related fractures. Can Med Assoc J 2008; 179: 319-326.
7. Kuo HW, Tsai SS, Tiao MM, Yang CY. Epidemiologic features of CKD in Taiwan. Am J Kidney Dis 2007; 49: 46-55.
8. Chiang CW, Chen CY, Chiu HF, Wu HL, Yang CY. Trends in the use of antihypertensive drugs by outpatients with diabetes in Taiwan, 1997-2003. Pharmacoepidemiol Drug Saf 2007; 16: 412-421.
9. Tiao MM, Tsai SS, Kuo HW, Chen CL, Yang CY. Epidemiological features of biliary atresia in Taiwan, a national study 1996-2003. J Gastroenterol Hepatol 2008; 23: 62-66.
10. WHO Collaborating Center for Drugs Statistics Methodology. ATC Index With DDDs 2003, 2003; WHO: Oslo.
11. Vestergaard P, Mollerup CL, Frokjar VG, et al. Cohort study of risk of fracture before and after surgery for primary hyperparathyroidism. Br Med J 2000; 321: 598-602.
12. Ivanovich P, Fellows H, Rich C. The absorption of calcium carbonate. Ann Intern Med 1967; 66: 917-923.
13. Nordin BE. Calcium and osteoporosis. Nutrition 1997; 13: 664-686.
14. Sheikh MS, Santa Ana CA, Nicar MJ, Schiller LR, Fordtran JS. Gastrointestinal absorption of calcium from milk and calcium salts. N Engl J Med 1987; 317: 532-536.
15. Chonan O, Takahashi R, Yasui H, Watanuki M. Effect of L-lactic acid on calcium absorption in rats fed omeprazole. J Nutr Sci Vitaminol 1998; 44: 473-481.
16. Chonan O, Takahashi R, Yasui H, Watanuki M. Effect of L-lactic acid on the absorption of calcium absorption in gastrectomized rats. J Nutr Sci Vitaminol 1998; 44: 869-875.
17. Chie WC, Yang RS, Liu JP, Tsai KS. High incidence rate of hip fracture in Taiwan: estimated from a nationwide health insurance database. Osteoporos Int 2004; 15: 998-1002.
18. Huang KY, Chang JK, Ling SY, Endo N, Takahashi HE. Epidemiology of cervical and trochanteric fractures of the proximal femur in 1996 in Kaohsiung City, Taiwan. J Bone Miner Metab 2000; 18: 89-95.